Binx Health

What Binx Health does

Binx Health is a Boston-based healthcare technology company that develops and commercializes FDA-cleared, CLIA-waived molecular point-of-care diagnostic platforms focused on sexually transmitted infection testing. Its flagship product, the binx io, combines ultra-rapid polymerase chain reaction (PCR) amplification with a proprietary electrochemical detection method to deliver central-laboratory-grade chlamydia and gonorrhea results in approximately 30 minutes, enabling single-visit "test-and-treat" workflows for both male and female patients in non-laboratory settings. The company has historically also operated the binx everywhere physician-mediated digital platform for at-home sample collection; in December 2023 it divested that consumer testing business to imaware, retaining and refocusing on the point-of-care molecular diagnostics franchise.

The company operates a hybrid razor/blade revenue model: the binx io instrument is either sold directly or placed under the November 2022 Reagent Rental Program that eliminates upfront capex for CLIA-waived facilities, while recurring revenue is generated through sale of CT/NG assay cartridges and reagents on each test performed. Established CPT reimbursement codes (87491, 87591, 87801) align clinic and binx economics. Go-to-market is multi-channel — a direct commercial team plus national distribution agreements with Cardinal Health, Fisher Healthcare (Thermo Fisher), McKesson, and Medline, the Afaxys GPO for public/community health clinics, and partnerships with state health departments (North Dakota, Alabama), student health insurers (Wellfleet), nonprofits (Elton John AIDS Foundation, Birmingham AIDS Outreach), and pharmacy/affordable-care players (Mark Cuban Cost Plus Drug Company). Commercial footprint spans over 1,200 clinic locations as of mid-2024.

Binx Health has raised approximately $169 million in disclosed equity funding, including a $104 million Series E led by OrbiMed in May 2021 and a $65 million Series F co-led by Hildred Capital and EQT Life Sciences in April 2024. Manufacturing is conducted through partners in the United States, China, Ireland (notably Harmac Medical Products), and Germany. The company holds FDA 510(k) clearance, CLIA-waived status, and CE-mark for European distribution, and operates dual legal entities in Massachusetts (binx health, inc.) and the United Kingdom (binx health Ltd.).

Name

Binx Health

Legal name

binx health, inc.

Website

https://mybinxhealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Binx Health is a Boston-based molecular diagnostics company whose FDA-cleared, CLIA-waived binx io platform delivers central-lab-quality chlamydia and gonorrhea results in ~30 minutes at the point of care, serving clinics, urgent care, public health departments, and community health networks across 1,200+ U.S. locations.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

akta.pro secondary industry

Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment (HLALAIAL)

Keywords

• Point-of-care diagnostics
• Molecular diagnostic platform
• STI testing technology
• CLIA-waived PCR testing
• Sexual health diagnostics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Point-of-Care Instrument Sales: Sale of binx io instruments to healthcare facilities. The company offers a reagent rental program that eliminates upfront instrument costs, providing instrument placement for CLIA-waived facilities.
2. Reagent and Assay Sales: Recurring revenue from sale of CT/NG assay cartridges and reagents for use with the binx io platform. Clinics purchase test cartridges for each patient test performed.
3. Reimbursement Codes: Established CPT reimbursement codes (87491 and 87591, or 87801) provide additional revenue stream for clinics and hospitals using the platform, creating alignment between binx and healthcare providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Binx Health develops and sells the binx io, an FDA-cleared, CLIA-waived molecular point-of-care testing platform that delivers central-lab-quality chlamydia and gonorrhea results in approximately 30 minutes from male urine and female vaginal swab specimens, enabling single-visit diagnosis and treatment. The company also operates the binx everywhere digital health platform for physician-mediated at-home STI/HIV self-collection and follow-up, and offers a reagent rental program that places binx io instruments in CLIA-waived facilities with no upfront cost.

Product overview

Binx Health offers a dual-care omnichannel platform consisting of two main product lines: (1) binx io, an FDA-cleared, CLIA-waived molecular point-of-care testing platform that provides rapid (~30 minute) laboratory-quality results for chlamydia and gonorrhea testing in both males and females, enabling single-visit diagnosis and treatment; and (2) binx everywhere, a physician-mediated digital platform and logistics solution that enables convenient at-home self-collection of samples for STI/HIV testing, processed through a network of partner reference laboratories with clinical follow-up. The company also offers a reagent rental program for instrument placement at CLIA-waived facilities.

Differentiator

Problem solved

Functional benefit

Brands

• binx io: FDA-Cleared, CLIA-Waived molecular point-of-care testing platform for chlamydia and gonorrhea detection providing results in about 30 minutes.
• binx everywhere

Products and services

• binx io

Quantifiable outcome

• 63% reduction in inappropriate antibiotic treatment with binx io compared to standard of care
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

15 partnerships are on record, tiered core and flagship.

• Massachusetts General Hospital (MGH)coreStrategic or Co-development Partner · 23 January 2025Clinical study collaboration assessing real-world impact of Point of Care testing for CT and NG testing in symptomatic patients at MGH sexual health clinic. Study showed 63% reduction in inappropriate antibiotic treatment with binx io.
• Harmac Medical ProductscoreTechnology or Integration · 2 July 2024Manufacturing partnership with Harmac Medical Products' Ireland division to support capacity expansion and low cost-of-goods manufacturing. With global manufacturing in US, Europe and APAC, including partners in China, Ireland and Germany.
• McKessoncoreChannel Partner/ Reseller/ Distributor · 2 April 2024National partnership agreement as part of the company's distribution network expansion alongside Fisher Healthcare, Cardinal Health, and Medline.
• MedlinecoreChannel Partner/ Reseller/ Distributor · 2 April 2024National partnership agreement as part of the company's distribution network expansion alongside Fisher Healthcare, Cardinal Health, and McKesson.
• Cardinal HealthcoreChannel Partner/ Reseller/ Distributor · 12 February 2024National distribution agreement to expand access to binx io through Cardinal Health's network serving 90% of US hospitals, 29,000 pharmacies, and 10,000 specialty physician offices and clinics. This collaboration provides access to acute clinical care settings via Cardinal Health's vast sales network.
• imawarecoreOthers · 4 December 2023Acquisition of binx health's at-home consumer testing business by imaware. binx retained and continues to grow its point-of-care molecular diagnostics business. Consumer division had delivered millions of tests and generated tens of millions of dollars in revenue.
• Fisher Healthcare (Thermo Fisher Scientific)coreChannel Partner/ Reseller/ Distributor · 27 November 2023Non-exclusive national distribution agreement to expand rollout of binx io to CLIA-waived locations including urgent care, student health centers, community health clinics, emergency departments, OB/GYN, and primary care offices across the country.
• Mark Cuban Cost Plus Drug CompanycoreStrategic or Co-development Partner · 24 April 2023Collaboration to offer at-home access to affordable testing and prescription medications. Patients access testing through binx everywhere digital platform and receive affordable medication through Cost Plus Drugs online prescription program.
• Elton John AIDS FoundationflagshipStrategic or Co-development Partner · 7 March 2023Joint initiative to increase access to testing for HIV, STIs, and pre-exposure prophylaxis (PrEP) nationally. Self-collection kits made available through Elton John AIDS Foundation custom branded website with cash pay and insurance billing options for comprehensive PrEP and HIV/STI screening program.
• Birmingham AIDS OutreachcoreStrategic or Co-development Partner · 1 March 2023Sassy Little Box program partnership to enable access to HIV and STI testing at the community level. Targets high-risk communities in greater Birmingham area through local partnerships and grassroots organizations serving LGBTQ+, Latino, and Black communities.
• AfaxyscoreChannel Partner/ Reseller/ Distributor · 10 November 2022Strategic supply agreement through Afaxys Group Purchasing Organization to expand access to sexual health testing nationally. Provides thousands of community and public health clinics across the US access to binx point-of-care and digital health offerings under preferred pricing with joint marketing outreach.
• Alabama Department of Public HealthcoreStrategic or Co-development Partner · 4 October 2022First-of-its-kind partnership enabling STI/HIV self-collection kits available to order online and mailed to any Alabama resident. Significant increase in uptake of self-collection kits across all Alabama counties, including rural communities.
• WellfleetcoreStrategic or Co-development Partner · 4 May 2022Partnership with student health insurer (Berkshire Hathaway company) to broaden access to HPV testing through convenient, at-home sample collection via binx everywhere platform. Aligned with Biden Administration's Cancer Moonshot initiative.
• North Dakota Department of Public HealthcoreStrategic or Co-development Partner · 15 February 2022Partnership to combat spread of STIs by enabling North Dakota residents ages 14+ to discreetly obtain at-home sample collection kits at no cost. Supports PrEP services with quarterly STI screening and HIV testing.
• WellfleetcoreGTM or Marketing Partner · 8 December 2021Expanded agreement to provide college students nationwide access to STI testing through binx everywhere at-home and in-dorm digital platform. Covers all colleges and universities offering Wellfleet student health insurance.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert system is a leading point-of-care molecular diagnostics platform used for infectious disease testing including CT/NG. Binx io directly competes with GeneXpert in CLIA-waived and near-patient molecular testing settings.
• GenMark Diagnostics (Roche): GenMark's ePlex system provides rapid molecular diagnostics for infectious diseases, now part of Roche. As a direct peer in syndromic and infectious disease molecular testing, GenMark competes with Binx in POC settings.
• Qiagen: Qiagen offers the QIAstat-Dx molecular diagnostic platform for syndromic and infectious disease testing at the point of need. Qiagen is a direct peer in POC molecular diagnostics with comparable target customers.
• Hologic: Hologic's Aptima Combo 2 is the market-leading NAAT test for chlamydia and gonorrhea, primarily run on the Panther system in central labs. Hologic directly competes with Binx Health in CT/NG testing and women's sexual health diagnostics.
• bioMérieux (BioFire): BioFire's FilmArray syndromic molecular panels compete in the point-of-care molecular diagnostics space, including STI-related testing. Both companies target rapid, decentralized infectious disease diagnostics.
• QuidelOrtho: QuidelOrtho specializes in rapid diagnostic testing, including molecular assays for infectious diseases. The company is a direct peer in the rapid and POC molecular diagnostics market.

Broad incumbents

• Becton Dickinson (BD): BD offers the BD MAX system and Veritor Plus platform for molecular and rapid antigen diagnostics. As a broad incumbent in diagnostics, BD competes with Binx across both POC and central lab testing categories.
• Roche Diagnostics: Roche offers the cobas Liat and other molecular POC platforms for infectious disease testing, plus a dominant central lab installed base. As a broad incumbent, Roche competes across multiple segments where Binx operates.
• Abbott Diagnostics: Abbott's ID NOW and m-POC systems compete in rapid molecular diagnostics, and the company has a large central lab diagnostics franchise. Abbott is a broad incumbent with overlapping capabilities in POC infectious disease testing.

Emerging players

• T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics, primarily for sepsis. While focused on a different clinical indication, it represents an emerging peer in the rapid molecular diagnostics category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/binxhealth
• Xx.com/BinxHealth
• Facebookfacebook.com/binxhealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds9 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Binx Health